20924633

Source:http://linkedlifedata.com/resource/pubmed/id/20924633

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0079459, umls-concept:C0457083, umls-concept:C0746883, umls-concept:C0750729, umls-concept:C1442455
pubmed:issue	2
pubmed:dateCreated	2011-4-7
pubmed:abstractText	In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9616295
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine, http://linkedlifedata.com/resource/pubmed/chemical/lenograstim
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1437-7772
pubmed:author	pubmed-author:AzumaTaichiT, pubmed-author:HatoTakaakiT, pubmed-author:HorikawaTamamiT, pubmed-author:NarumiHiroshiH, pubmed-author:ShikataHisaharuH, pubmed-author:TakaokaIkueI, pubmed-author:TakeuchiKazuhitoK, pubmed-author:YakushijinYoshihiroY, pubmed-author:YamanouchiJunJ, pubmed-author:YasukawaMasakiM
pubmed:issnType	Electronic
pubmed:volume	16
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	118-24
pubmed:dateRevised	2011-9-13
pubmed:meshHeading	pubmed-meshheading:20924633-Aged, pubmed-meshheading:20924633-Antibiotics, Antineoplastic, pubmed-meshheading:20924633-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20924633-Cost-Benefit Analysis, pubmed-meshheading:20924633-Cyclophosphamide, pubmed-meshheading:20924633-Doxorubicin, pubmed-meshheading:20924633-Drug Administration Schedule, pubmed-meshheading:20924633-Female, pubmed-meshheading:20924633-Fever, pubmed-meshheading:20924633-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:20924633-Humans, pubmed-meshheading:20924633-Leukocytes, pubmed-meshheading:20924633-Lymphoma, Large B-Cell, Diffuse, pubmed-meshheading:20924633-Male, pubmed-meshheading:20924633-Middle Aged, pubmed-meshheading:20924633-Neutropenia, pubmed-meshheading:20924633-Neutrophils, pubmed-meshheading:20924633-Prednisone, pubmed-meshheading:20924633-Recombinant Proteins, pubmed-meshheading:20924633-Vincristine
pubmed:year	2011
pubmed:articleTitle	Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
pubmed:affiliation	Cancer Center of Ehime University Hospital, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 7910295, Japan. yoshiyak@m.ehime-u.ac.jp
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial